- Home
- CNTB vs MAIA Comparison
CNTB vs MAIA Comparison
Compare CNTB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- MAIA
- Stock Information
- Founded
- CNTB 2012
- MAIA 2018
- Country
- CNTB United States
- MAIA United States
- Employees
- CNTB N/A
- MAIA N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- MAIA Health Care
- Exchange
- CNTB Nasdaq
- MAIA Nasdaq
- Market Cap
- CNTB 68.5M
- MAIA 62.4M
- IPO Year
- CNTB 2021
- MAIA 2022
- Fundamental
- Price
- CNTB $1.17
- MAIA $2.82
- Analyst Decision
- CNTB Strong Buy
- MAIA
- Analyst Count
- CNTB 1
- MAIA 0
- Target Price
- CNTB $8.00
- MAIA N/A
- AVG Volume (30 Days)
- CNTB 24.6K
- MAIA 60.0K
- Earning Date
- CNTB 09-05-2024
- MAIA 11-05-2024
- Dividend Yield
- CNTB N/A
- MAIA N/A
- EPS Growth
- CNTB N/A
- MAIA N/A
- EPS
- CNTB N/A
- MAIA N/A
- Revenue
- CNTB $24,116,000.00
- MAIA N/A
- Revenue This Year
- CNTB N/A
- MAIA N/A
- Revenue Next Year
- CNTB $63.90
- MAIA N/A
- P/E Ratio
- CNTB N/A
- MAIA N/A
- Revenue Growth
- CNTB N/A
- MAIA N/A
- 52 Week Low
- CNTB $0.68
- MAIA $0.82
- 52 Week High
- CNTB $2.84
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- CNTB 44.02
- MAIA 50.98
- Support Level
- CNTB $1.18
- MAIA $2.36
- Resistance Level
- CNTB $1.26
- MAIA $2.72
- Average True Range (ATR)
- CNTB 0.07
- MAIA 0.22
- MACD
- CNTB -0.01
- MAIA 0.02
- Stochastic Oscillator
- CNTB 13.59
- MAIA 72.28
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.